5 Revealing Analyst Questions From Regeneron’s Q3 Earnings Call
Update: 2025-11-04
Description
Regeneron's Q3 results impress, driving stock price up: The company's key drugs, Dupixent, Libtayo, and EYLEA HD, saw double-digit sales growth, offsetting flat overall revenue. Regeneron beat Wall Street estimates with $3.75 billion in revenue and $11.83 adjusted earnings per share. The company is focusing on building its own manufacturing plant and is open to deals but not actively pursuing mergers or acquisitions. Investors are watching for regulatory decisions and clinical trial updates, with Regeneron's stock price climbing to $640.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
